Phase 4 N=9 Growth Hormone and Endothelial Function in Children
Growth Hormone Deficiency · Panhypopituitarism · Short Stature
Primary: Reactive Hyperemic Response After 3 Months of Growth Hormone — 21.077 ml/dl min — p=0.644
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=44 Effect of DPP4 Inhibition on Growth Hormone Secretion
Obesity
Primary: Aim 1: Stimulated Peak Growth Hormone Level — 5.2; 3.1; 1.9; 2.0 ng/ml
Phase 4 N=437 Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin
Diabetes · Type 2 Diabetes Mellitus
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.66; -1.52 Percentage (%) of HbA1c — p=0.2601
Phase 4 N=63 Intraoperative Infusion of Precedex to Reduce Length of Stay After Lumbar Spine Fusion
Spinal Fusion Acquired · Spinal Stenosis · Lesions of Lumbosacral Intervertebral Disc
Primary: Time Required After Surgery to Reach Fitness for Discharge From Hospital — 3.2; 3.2 days — p=0.36
Phase 4 N=15 A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise
Depression · Depressive Disorder, Major · Depressive Disorder
Primary: Number of Participants Experiencing Remission — 0; 2; 4; 2 Participants
Phase 4 N=17 Feasibility of Prophylactic Haldol to Prevent Delirium in Cancer Patients
Stem Cell Transplant Complications · Delirium
Primary: Side Effects and Tolerability of Haldol in Patients With Undergoing Hematopoietic Stem Cell Transplant — 1 Adverse Event
Phase 4 N=27 Intravesicular Onabotulinumtoxin A in Interstitial Cystitis
Interstitial Cystitis
Primary: The Primary Outcome Will be Assessing the Measurement of Subjective Patient Pain Using the O'Leary-Sant Symptom and Problem Indexes. — 10.92; 10.85; 9.75; 9.92 units on…
Phase 4 N=81 Vascular Inflammation in Psoriasis - Extension Study
Psoriasis · Cardiovascular Disease
Primary: Change in Vascular Inflammation — -3.8 percentage change
Phase 4 N=97 Vascular Inflammation in Psoriasis Trial (The VIP Trial)
Psoriasis · Cardiovascular Disease
Primary: Change in Vascular Inflammation — -.067; -.052; -.079 Tissue-to-background ratio (TBR) — p=0.795
Phase 4 N=108 Neuromuscular Blockade During Transurethral Resection of Bladder Cancer
Neuromuscular Blockade
Primary: Number of Participants Attaining a 5 (Optimal) Surgical Condition Score — 16; 38 Participants
Phase 4 N=96 The Effect of Deep Block Versus Moderate Block on the Stress Response After Laparoscopic Gastrectomy
Neuromuscular Blockade
Primary: IL-6 — 84; 70.14 pg / ml
Phase 4 N=116 Comparison of Vaccination Routes: Subcutaneous Versus Intramuscular Application of FSME-Immun®
Vaccine Efficacy
Primary: Humoral Immunity to TBE (Tick-borne Encephalitis) Vaccine — 574.8; 612.0 Geometric mean titers
Phase 4 N=41 Sequencing Treatments for Mothers With ADHD and Their At - Risk Children
Attention Deficit Hyperactivity Disorder
Primary: Child Behavioral Functioning — 4.78; 4.56; 4.44; 4.67 units on a scale
Phase 4 N=40 Fluticasone Furoate Treatment of Daytime Somnolence and Cognitive Performance in Seasonal Allergic Rhinitis
Seasonal Allergic Rhinitis
Primary: Performance on Test of Variables of Attention (TOVA) - a Standardized Test of Cognitive Performance — 2.63; 3.95; 1.20; 1.83 number of errors
Phase 4 N=90 Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction
Heart Failure, Diastolic
Primary: Percent Change in Serum Creatinine at 72 Hours. — 4; 11; 5; 20 percent change in serum creatinine